You are here

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

Last updated on February 17, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Miami, Florida, 33169 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer's Disease, Huntington's Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and/or female subjects between the ages of 18 and 75 years, inclusive

- For severe renal impairment group, subjects with creatinine clearance of less than 30
mL/min, but not yet on dialysis and in good general health commensurate with the
population with chronic renal disease; however, subjects with type 1 and 2 diabetes
that are reasonably controlled and who do not have a predisposition to severe
hypoglycemia can both be included.

- For normal renal function group, healthy subjects with creatinine clearance of greater
than 80mL/min and demographically comparable to subjects with impaired renal function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant or nursing women; women of childbearing potential (WOCBP) who are unwilling
or unable to use an acceptable method of contraception as outlined in the protocol
from at least 14 days prior to the first dose of study medication.

- For normal renal function group, use of prescription or non-prescription drugs,
vitamins, or dietary supplements within 7 days of 5 half-lives (whichever is longer)
prior to the first dose of study medication.

Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to
the first dose of study medication. Acetaminophen at doses of ? 2 grams/day is permitted.

- For renal impairment group, a known history of clinically significant coronary heart
disease, cerebrovascular disease or peripheral vascular disease and/or an
event/intervention during the past 6 months. Systemic therapy with CYP3A or CYP2D6
inhibitors within 7 days or 5 halflives (whichever is longer) prior to the first dose
of trial medication.

NCT00824590
Pfizer
Completed
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now